A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments (DELIVER)
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Sponsor: H. Lundbeck A/S
Listed as NCT04418765, this PHASE3 trial focuses on Migraine and remains completed. Sponsored by H. Lundbeck A/S, it has been updated 19 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
19 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 14 earlier versions
-
Nov 2022 — Oct 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
Status: Completed → Active Not Recruiting
-
Nov 2021 — Feb 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE3
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lundbeck A/S
For direct contact, visit the study record on ClinicalTrials.gov .